Therapeutic progress of postmenopausal osteoporosis

Xu LI,Wenpei BAI,Zhonghou LIU

DOI: https://doi.org/10.3969/j.issn.1006-7108.2007.09.001

2007-01-01

Abstract:With more and more attention from people and greatly increase of research, the therapeutic progress of osteoporosis related to menostasia is going forward rapidly in recent years. This article reviews Design Principles of treatment, drug therapy, non-drug therapy and so on.

What problem does this paper attempt to address?

Research and Application of Target Therapy for Osteoporosis

WANG Ying,YANG Yun-mei

DOI: https://doi.org/10.3969/j.issn.1674-8115.2012.08.030

2012-01-01

Abstract:Osteoporosis is a common disease which is caused by a systemic impairment of bone mass and microarchitecture.The disease is likely to occur in the elderly,especially in postmenopausal women.Along with the understanding of the detailed molecular biology of bone cells,the signaling network of the communication between bone-forming osteoblasts and bone-resorbing osteoclasts has been revealed,which has led to the identification of novel therapeutic targets.Novel treatment strategy aims to inhibit excessive bone resorption and increase bone formation.The most promising novel drugs include denosumab(a monoclonal antibody for a key osteoclast cytokine),odanacatib(a specific inhibitor of the osteoclast protease cathepsin K) and two endogenous inhibitors of bone formation(antibodies against the proteins sclerostin and dickkopf-1).This review will discuss the underlying physiology of novel therapies and explore their further applications.
Recent Progresses in the Treatment of Osteoporosis

Shan-Shan Li,Shi-Hao He,Peng-Yu Xie,Wei Li,Xin-Xin Zhang,Tian-Fang Li,Dai-Feng Li

DOI: https://doi.org/10.3389/fphar.2021.717065

IF: 5.6

2021-07-22

Frontiers in Pharmacology

Abstract:Osteoporosis (OP) is a chronic bone disease characterized by aberrant microstructure and macrostructure of bone, leading to reduced bone mass and increased risk of fragile fractures. Anti-resorptive drugs, especially, bisphosphonates, are currently the treatment of choice in most developing countries. However, they do have limitations and adverse effects, which, to some extent, helped the development of anabolic drugs such as teriparatide and romosozumab. In patients with high or very high risk for fracture, sequential or combined therapies may be considered with the initial drugs being anabolic agents. Great endeavors have been made to find next generation drugs with maximal efficacy and minimal toxicity, and improved understanding of the role of different signaling pathways and their crosstalk in the pathogenesis of OP may help achieve this goal. Our review focused on recent progress with regards to the drug development by modification of Wnt pathway, while other pathways/molecules were also discussed briefly. In addition, new observations made in recent years in bone biology were summarized and discussed for the treatment of OP.

pharmacology & pharmacy
The clinical progress in the treatment of postmenopausal osteoporosis using traditional Chinese medicine

Haiyang WU,Huan SUO,Ping WANG

DOI: https://doi.org/10.3969/j.issn.1006-7108.2015.02.026

2015-01-01

Abstract:Postmenopausal osteoporosis is a common and popular disease in postmenopausal women.Its basic pathogenesis is metabolic imbalance of bone formation and bone absorption caused by a decline of ovarian function and a drop in estrogen level.The characteristics of the disease are bone mass loss of the whole body, the breakdown of bone microstructure, bone pain, and the increase of fracture risk.A great quantity of research indicates that traditional Chinese medicine treatment for postmenopausal osteoporosis can improve the bone mineral density of postmenopausal women and reduce the symptom of bone pain.It has distinct advantage.Currently, the research in postmenopausal osteoporosis mainly includes the experimental research of single Chinese herb and the clinical research of Chinese compound formula.This paper summarizes recent experiment development of three commonly used Chinese herbs from bone measurement index, the change of cytokines, and gene level aspects according to the pathogenesis and medication frequency of postmenopausal osteoporosis.In Chinese compound use aspects, it is believed that kidney deficiency is the main pathogenesis of postmenopausal osteoporosis.Liver and spleen deficiency and blood stigma are also involved.The paper elucidates the application of kidney-nourishing therapy in postmenopausal osteoporosis, and explores the possible future research direction for postmenopausal osteoporosis therapy.
Research progress of osteoporosis drug treatment

GAO Kai,LI Yun-xia,CHEN Shi-yi

DOI: https://doi.org/10.3969/j.issn.1006-1533.2012.15.005

2012-01-01

Abstract:With the coming of the aging society,the morbidity of osteoporosis has gradually been increasing and has become a serious public health problem affecting the health of postmenopausal women and the elderly so that it results in a huge economic and social burden.The action mechanism of the drugs to treat osteoporosis mainly includes two categories: antiresorptive and promote bone formation.This article reviews the research progress of the osteoporosis drug treatment.
Mechanistic Advances in Osteoporosis and Anti-Osteoporosis Therapies.

Haiwei Wang,Yuchuan Luo,Haisheng Wang,Feifei Li,Fanyuan Yu,Ling Ye

DOI: https://doi.org/10.1002/mco2.244

2023-01-01

MedComm

Abstract:Osteoporosis is a type of bone loss disease characterized by a reduction in bone mass and microarchitectural deterioration of bone tissue. With the intensification of global aging, this disease is now regarded as one of the major public health problems that often leads to unbearable pain, risk of bone fractures, and even death, causing an enormous burden at both the human and socioeconomic layers. Classic anti-osteoporosis pharmacological options include anti-resorptive and anabolic agents, whose ability to improve bone mineral density and resist bone fracture is being gradually confirmed. However, long-term or high-frequency use of these drugs may bring some side effects and adverse reactions. Therefore, an increasing number of studies are devoted to finding new pathogenesis or potential therapeutic targets of osteoporosis, and it is of great importance to comprehensively recognize osteoporosis and develop viable and efficient therapeutic approaches. In this study, we systematically reviewed literatures and clinical evidences to both mechanistically and clinically demonstrate the state-of-art advances in osteoporosis. This work will endow readers with the mechanistical advances and clinical knowledge of osteoporosis and furthermore present the most updated anti-osteoporosis therapies.
Research Progress of Postmenopausal Osteoporosis Treated with Chinese Medicine

Juan-juan PENG,Bing WANG,Xu-dong WANG

DOI: https://doi.org/10.16367/j.issn.1003-5028.2016.05.0387

2016-01-01

Abstract:Postmenopausal osteoporosis (PMOP) is of high incidence among postmenopausal women.Many western medicine therapies are applicable to PMOP but not advisable for long-term use for their great side effects.Chinese medicine therapy has significant effects on PMOP,which can not only restore the sclerotin but also increase the bone mass.Chinese medicine therapy regulates the functional state of the whole body in a dialectical manner,regulating the endocrine and enhancing the general immunity of the patients simultaneously to achieve comprehensive therapeutic effect.Besides,Chinese medicine therapy is advisable for long-time application for its little side effect.However,the occurrence rate of PMOP is increasing since premature ovarian failure keeps rising in the incidence rate of and it tends to attack younger people.It is expected that more studies on the preventive treatment of Chinese medicine can be conducted,and this is also in accord with the TCM concept of "superior doctor treat disease before it attacks".
Advances in Materials-Based Therapeutic Strategies Against Osteoporosis.

Chen Lei,Jing-han Song,Song Li,Yi-na Zhu,Ming-yi Liu,Mei-chen Wan,Zhao Mu,Franklin R. Tay,Li-na Niu

DOI: https://doi.org/10.1016/j.biomaterials.2023.122066

IF: 14

2023-01-01

Biomaterials

Abstract:Osteoporosis is caused by the disruption in homeostasis between bone formation and bone resorption. Conventional management of osteoporosis involves systematic drug administration and hormonal therapy. These treatment strategies have limited curative efficacy and multiple adverse effects. Biomaterials-based therapeutic strategies have recently emerged as promising alternatives for the treatment of osteoporosis. The present review summarizes the current status of biomaterials designed for managing osteoporosis. The advantages of biomaterials-based strategies over conventional systematic drug treatment are presented. Different anti-osteoporotic delivery systems are concisely addressed. These materials include injectable hydrogels and nanoparticles, as well as anti-osteoporotic bone tissue engineering materials. Fabrication techniques such as 3D printing, electrostatic spinning and artificial intelligence are appraised in the context of how the use of these adjunctive techniques may improve treatment efficacy. The limitations of existing biomaterials are critically analyzed, together with deliberation of the future directions in biomaterials-based therapies. The latter include discussion on the use of combination strategies to enhance therapeutic efficacy in the osteoporosis niche.
Progressing of anti-osteoporosis drug investigation

Nian LIU,Ze-neng CHENG,Huan-de LI

DOI: https://doi.org/10.3321/j.issn:1003-3734.2004.12.056

2004-01-01

Abstract:To review the drugs for treating osteoporosis after retrieving related articles through Medline and the China Pharmaceutical Abstract.Estrogen is one of the most important drugs to prevent and treat osteoporosis.But it can't be used wildly in clinical practice due to its side effects,e.g:the endometrial hyperplasia.Developing new dosage form to avoid adverse effects is in progressing.Selected estrogen receptor modulator,plant estrogen and Traditional Chinese Medicine(TCM)have good prospect in preventing and treatment for osteoporosis.Diphosphonate and calcium preparation are effective drug,but investigator found that it is difficult to develop more efficacious drug in this area.
Research progress on drugs in osteoporosis therapy

Wenbin JIA,Chao LIU,Yan ZOU

DOI: https://doi.org/10.3969/j.issn.1006-0111.2017.06.003

2017-01-01

Abstract:Osteoporosis (OP) is a systemic bone metabolism disease characterized by a systemic impairment of bone mass ,strength ,and microarchitecture ,which will be result in increasing the propensity of fragility fractures .In recent years , OP becomes a worldwide health problem and a hotspot in medical research due to its increasing incidence .Anti-resorptive drugs inhibit osteoclast differentiation and maturation in order to reduce bone resorption ;Bone-anabolic drugs promote the bone for-mation function of osteoblast and reconstruct bone tissue ;Bone mineralization-acceleration drugs are the basic material for pre-vention and treatment of osteoporosis ,including calcium and vitamin D ;Strontium ranelate is the representative drug of un-coupling agents .In this paper ,the current progress of osteoporosis treatments were reviewed including these proposed drugs .
The Present and Progress of Common Drug Therapy in Treating Senile Osteoporosis

Li Mo,Wang Haiwei,Wang Lijuan,Xiao Jianlin,Gao Zhongli,Cai Hanqing

DOI: https://doi.org/10.3877/cma.j.issn.2096-0263.2019.06.011

2019-01-01

Abstract:Osteoporosis is a very common disease among elderly people but still no effective therapy to cure. Drug therapy as the prevent treatment in osteoporosis has been proved valuable in releasing the clinical symptom and prevent the progress of fracture. With the increasing variety of osteoporosis drugs, the comprehension of the effect and side effect of drugs are growing. The laboratory and clinical studies of osteoporosis were reviewed, and the efficacy and safety of drug were summarized in this article, hopefully it can provide theoretical basis for clinical treatment of osteoporosis. Key words: Osteoporosis; Drug therapy; Bisophosphonates; Parathyroid hormone
Advances in the occurrence and biotherapy of osteoporosis.

Zi Zou,Wei Liu,Lihua Cao,Ying Liu,Tiantian He,Shuping Peng,Cijun Shuai

DOI: https://doi.org/10.1042/BST20200005

2020-01-01

Biochemical Society Transactions

Abstract:Osteoporosis (OP) is a bone metabolic disease, is characterized by degeneration of bone structure and decreased bone mass. It happens in more than 1/3 women and 1/5 men of over than 50 years old, which affects the health and lives of people. The main mechanism of OP is mainly that the dynamic balance between the bone formation and resorption is broken, so that bone resorption is more than bone formation. It is prone to result in bone metabolism disorder. There are many precipitating factor such as elder age, low hormone level, genetic factors and bad hobbies. At the same time, the occurrence of the OP and its complications has different degrees of impact on people's quality of life. Based on the current understanding of the OP, we summarized the etiology, current clinical drugs and potential targeting therapy for OP. Although the research have made many progress in explore what is the novel mechanism and how to improve the effect, there are still many problems in the treatment method that limit its application prospects and need to be solved. In this review, we mainly focus on the mechanism of OP and related research on the targeted treatment of OP. Hopefully, our summary will provide a reference to develop some novel strategies for the target therapy of OP.
Progress in Anti-Osteoporosis Drug Treatment

Xin Yi

2010-01-01

Abstract:Osteoporosis is a major public health problem in both women and men,characterized by low bone strength and increased risk of fracture.Agents for the treatment of osteoporosis are divided into two categories: anti-catabolic and anabolic.Anti-catabolic agents inhibit bone resorption by reducing the number and / or the activity of osteoclasts.A variety of antiresorptive agents are available,including bisphosphonates,estrogen and selective estrogen-receptor modulators,calcitonin and Denosumab.In 2010,Denosumab is approved by FDA and European Commission.Anabolic agents act by stimulating formation of new bone.The only anabolic agent currently available is recombinant human parathyroid hormone(rPTH).Strontium ranelate has been shown to be an antiosteoporotic agent that both increases bone formation and reduces bone resorption,resulting in a rebalance of bone turnover in favor of bone formation.With a better understanding of osteometabolic pathways,new forms of treatment are appearing on the horizon,such as glucagon-like peptide 2,calcilytics,cathepsin K inhibitors,sclerostin monoclonal antibody,etc.The treatment paradigm for osteoporosis will evolve further as promising new treatments progress through clinical development.
Osteoporosis treatment: current drugs and future developments

Ya-Jing Chen,Li-Hua Jia,Tao-Hong Han,Zhi-Hui Zhao,Jian Yang,Jun-Ping Xiao,Hong-Jun Yang,Ke Yang

DOI: https://doi.org/10.3389/fphar.2024.1456796

2024-08-12

Abstract:Osteoporosis is a common systemic metabolic disease characterized by a decrease in bone density and bone mass, destruction of bone tissue microstructure, and increased bone fragility leading to fracture susceptibility. Pharmacological treatment of osteoporosis is the focus of current research, and anti-osteoporosis drugs usually play a role in inhibiting bone resorption, promoting bone formation, and having a dual role. However, most of the drugs have the disadvantages of single target and high toxic and side effects. There are many types of traditional Chinese medicines (TCM), from a wide range of sources and mostly plants. Herbal plants have unique advantages in regulating the relationship between osteoporosis and the immune system, acupuncture therapy has significant therapeutic effects in combination with medicine for osteoporosis. The target cells and specific molecular mechanisms of TCM in preventing and treating osteoporosis have not been fully elucidated. At present, there is a lack of comprehensive understanding of the pathological mechanism of the disease. Therefore, a better understanding of the pathological signaling pathways and key molecules involved in the pathogenesis of osteoporosis is crucial for the design of therapeutic targets and drug development. In this paper, we review the development and current status of anti-osteoporosis drugs currently in clinical application and under development to provide relevant basis and reference for drug prevention and treatment of osteoporosis, with the aim of promoting pharmacological research and new drug development.
Advances in Pathogenesis and Therapeutic Strategies for Osteoporosis

Shasha Song,Yuanyuan Guo,Yuehua Yang,Dehao Fu

DOI: https://doi.org/10.1016/j.pharmthera.2022.108168

2022-01-01

Abstract:Osteoporosis, is the most common bone disorder worldwide characterized by low bone mineral density, leaving affected bones vulnerable to fracture. Bone homeostasis depends on the precise balance between bone resorption by osteoclasts and bone matrix formation by mesenchymal lineage osteoblasts, and involves a series of complex and highly regulated steps. Bone homeostasis will be disrupted when the speed of bone resorption is faster than bone formation. Based on various regulatory mechanisms of bone homeostasis, a series of drugs targeting osteoporosis have emerged in clinical practice, including bisphosphonates, selective estrogen receptor modulators, calcitonin, molecular-targeted drugs and so on. However, many drugs have major adverse effects or are unsuitable for long-term use. Therefore, it is very urgent to find more effective therapeutic drugs based on the new pathogenesis of osteoporosis. In this review, we summarize novel mechanisms involved in the pathological process of osteoporosis, including the roles of gut microbiome, autophagy, iron balance and cellular senescence. Based on the above pathological mechanism, we found promising drugs for osteoporosis treatment, such as: probiotics, alpha-ketoglutarate, senolytics and hydrogen sulfide. This new finding may provide an important basis for elucidating the complex pathological mechanisms of osteoporosis and provide promising drugs for clinical osteoporosis treatment.
Advances in Our Understanding of the Mechanism of Action of Drugs (including Traditional Chinese Medicines) for the Intervention and Treatment of Osteoporosis

Junjie Lu,Desheng Hu,Chen Ma,Bo Shuai

DOI: https://doi.org/10.3389/fphar.2022.938447

IF: 5.6

2022-06-14

Frontiers in Pharmacology

Abstract:Osteoporosis (OP) is known as a silent disease in which the loss of bone mass and bone density does not cause obvious symptoms, resulting in insufficient treatment and preventive measures. The losses of bone mass and bone density become more severe over time and an only small percentage of patients are diagnosed when OP-related fractures occur. The high disability and mortality rates of OP-related fractures cause great psychological and physical damage and impose a heavy economic burden on individuals and society. Therefore, early intervention and treatment must be emphasized to achieve the overall goal of reducing the fracture risk. Anti-OP drugs are currently divided into three classes: antiresorptive agents, anabolic agents, and drugs with other mechanisms. In this review, research progress related to common anti-OP drugs in these three classes as well as targeted therapies is summarized to help researchers and clinicians understand their mechanisms of action and to promote pharmacological research and novel drug development.

pharmacology & pharmacy
Narrative Review of Traditional Chinese Medicine in the Treatment of Postmenopausal Osteoporosis

Li Qi,Wang Wei-guo,Huang Xu-dong,Zhao Xiu-mei,XU Xiao-dong,Zhang Cheng-ming

DOI: https://doi.org/10.2174/0113862073259181231117055839

2024-01-17

Combinatorial Chemistry & High Throughput Screening

Abstract:Abstract: An increasing percentage of people in China are suffering from osteoporosis, particularly postmenopausal osteoporosis (PMOP), as the country rapidly evolves into an aging culture. Patients with osteoporosis are inclined to endure fractures, as well as deformities and impairments, which drastically decrease people’s quality of life. The benefits of traditional Chinese medicine (TCM) treatment have continued to become increasingly apparent as reports of adverse responses to Western medications increased. The main advantage of traditional Chinese medicine treatment is that pharmacological interactions may be employed to lessen adverse effects while increasing therapeutic efficacy. In addition, there are various exercise therapies created by medical doctors in the past generations, such as: Wuqinxi, Taijiquan, Baduanjin, Yijinjing, etc. Chinese medicine and exercise treatment for postmenopausal osteoporosis have garnered a lot of attention recently both domestically and internationally, and investigations demonstrate that these therapies have considerable therapeutic effects. The pathophysiology of postmenopausal osteoporosis, advancements of herbal therapy options, and exercise treatment options are all thoroughly addressed in this article.

pharmacology & pharmacy,biochemical research methods,chemistry, applied
Progresses of Chinese herbal medicine in treatment of osteoporosis

Ya-qi SUN,Yan-fang BIAN,Chun-na ZHOU,Le-yun MA,Su-xian WANG,Zhen CAI

DOI: https://doi.org/10.12025/j.issn.1008-6358.2018.20170801

2018-01-01

Abstract:Osteoporosis is a bone disease caused by a variety of reasons,being characterized by loss of bone mass, bone density reduction and being prone to fracture.In recent years,the researches of traditional Chinese medicine in treating osteoporosis are increasing.It is shown that some traditional Chinese medicines have effects on promoting bone formation and inhibiting bone resorption,which can be applied in prevention and treatment of osteoporosis.In this paper,the efficacies of some Chinese herbal medicines on osteoporosis as well as their related mechanisms were briefly summarized.
Advance on Treating Osteoporosis by Acupuncture and Moxibustion

Yawen SONG,Wanying LANG,Yajun WANG

DOI: https://doi.org/10.13193/j.issn.1673-7717.2016.06.011

2016-01-01

Abstract:The osteoporosis was a kind of bone degenerative disease in women.The prevention and treatment of them have been an urge health problem in human.This is a review mainly containing the context of methods and treatment for treating osteoporosis in recent decades at home and abroad.There were some evidences existing in the study:to stimulate the regulating function:to improve the levels of endogenous hormone;to improve the function of spleen and stomach;to strengthen the patients' absorption of drugs and various nutrients utilization;to improve the bone mineral content and bone mineral density;to reduce the number of microscopic fracture and the occurrence of new fracture;to improve the clinical symptoms and so on.From now on,we should study the effect and safe formulation about individual treatment,improve the quality of methods in clinic and explore the complex treating characters of evaluation method for the osteoporosis.
Emerging Therapeutic Targets for Osteoporosis Treatment.

Minglei Chen,Hongzhi Qiao,Zhigui Su,Huipeng Li,Qineng Ping,Li Zong

DOI: https://doi.org/10.1517/14728222.2014.912632

IF: 6.797

2014-01-01

Expert Opinion on Therapeutic Targets

Abstract:Introduction: To date, osteoporosis still remains a major public health burden especially for the aging populations. Over the last few decades treatments for osteoporosis have largely focused on anti-resorptive agents represented by bisphosphonates and estrogen therapy that dominated the market. Unsatisfactory efficacy, non-specificity and long-term safety of current therapies necessitate the need for new targets effectively preventing and treating of osteoporosis.Areas covered: This review expatiates on the mechanism of osteoporosis occurrence and bone remodeling cycle in detail. New targets of antiresorptive and anabolic agents based on the functions of osteoblasts and osteoclasts as well as associated signaling pathways are outlined.Expert opinion: Advanced understanding in the fields of bone remodeling, functions of osteoblasts, osteoclasts and osteocytes associated with osteoporosis occurrence offers the emerging bone-resorptive or bone-formative targets. Currently, molecules involving RANK-RANKL-OPG system and Wnt/beta-catenin signaling pathway act as the most promising targets.
Prospect of Combination and Sequential Therapies for Postmenopausal Osteoporosis.

Hao Liu,Binbin Li

DOI: https://doi.org/10.2174/1381612823666170516124224

IF: 3.31

2017-01-01

Current Pharmaceutical Design

Abstract:Background: Osteoporosis is a systemic bone disease, which is associated with the osteoporotic fracture. Along with prolonged life expectancy, the fracture risk increases dramatically with age. So far, it is usually the first choice to using antiresorptive agents. However, current clinical therapeutic treatments are not enough to inhibit the long-term bone loss and the rising risk of bone fractures. Recently, combination and sequential therapies with anti-osteoporosis drugs have become an inevitable trend. Objective: The purpose of this review is to summarize the present knowledge related to the combination and sequential therapies with anti-osteoporosis drugs. Methods: All articles published in PubMed until 2016 on the combination and sequential therapies with anti-osteoporosis drugs were reviewed and the relevant literature was described in this review. Results: As the first-line therapy for osteoporosis, the long-term safety and efficacy on bisphosphonate, teriparatide, and new anti-osteoporosis drugs are ongoing concerns. Combination or sequential therapies of bone-forming agents and anti-resorptive agents, or two kinds of anti-resorptive agents, or strontium ranelate and other anti-osteoporosis agents have the advantages on BMD compared with monotherapy. Conclusion: So far, it is still an important public health strategy to therapy on the osteoporosis and related fracture. Alternatively, the combination and sequential therapies with anti-osteoporosis drugs are promising approaches for prevention and treatment of osteoporosis and have far-reaching significance.

Therapeutic progress of postmenopausal osteoporosis

Research and Application of Target Therapy for Osteoporosis

Recent Progresses in the Treatment of Osteoporosis

The clinical progress in the treatment of postmenopausal osteoporosis using traditional Chinese medicine

Research progress of osteoporosis drug treatment

Mechanistic Advances in Osteoporosis and Anti-Osteoporosis Therapies.

Research Progress of Postmenopausal Osteoporosis Treated with Chinese Medicine

Advances in Materials-Based Therapeutic Strategies Against Osteoporosis.

Progressing of anti-osteoporosis drug investigation

Research progress on drugs in osteoporosis therapy

The Present and Progress of Common Drug Therapy in Treating Senile Osteoporosis

Advances in the occurrence and biotherapy of osteoporosis.

Progress in Anti-Osteoporosis Drug Treatment

Osteoporosis treatment: current drugs and future developments

Advances in Pathogenesis and Therapeutic Strategies for Osteoporosis

Advances in Our Understanding of the Mechanism of Action of Drugs (including Traditional Chinese Medicines) for the Intervention and Treatment of Osteoporosis

Narrative Review of Traditional Chinese Medicine in the Treatment of Postmenopausal Osteoporosis

Progresses of Chinese herbal medicine in treatment of osteoporosis

Advance on Treating Osteoporosis by Acupuncture and Moxibustion

Emerging Therapeutic Targets for Osteoporosis Treatment.

Prospect of Combination and Sequential Therapies for Postmenopausal Osteoporosis.